General Information of Drug (ID: DM86WI0)

Drug Name
ADX-1612 Drug Info
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM86WI0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RNS-60 DMDNRU1 Asthma CA23 Phase 2 [3]
LAM-003 DMQHWMJ Acute myeloid leukaemia 2A60 Phase 1 [4]
RTA 901 DMA6JME Diabetic neuropathy 8C0Z Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 (HSP90) TTO7FVG NOUNIPROTAC Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of Aldeyra Therapeutics
2 Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2023 Mar 6;24(5):5014.
3 Clinical pipeline report, company report or official report of Revalesio.
4 LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673.
5 Clinical pipeline report, company report or official report of Reata Pharmaceuticals.